CSL Beheer

Beheer criteriumcontroles 1/4

De CEO CSL is Paul McKenzie, benoemd in Mar2023, heeft een ambtstermijn van 1.58 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 8.18M, bestaande uit 23.1% salaris en 76.9% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.006% van de aandelen van het bedrijf, ter waarde CHF 4.68M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.6 jaar en 4 jaar.

Belangrijke informatie

Paul McKenzie

Algemeen directeur

US$8.2m

Totale compensatie

Percentage CEO-salaris	23.1%
Dienstverband CEO	1.6yrs
Eigendom CEO	0.006%
Management gemiddelde ambtstermijn	1.6yrs
Gemiddelde ambtstermijn bestuur	4yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Paul McKenzie's beloning veranderd ten opzichte van CSL's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	US$8m	US$2m	US$3b
Mar 31 2024	n/a	n/a	US$3b
Dec 31 2023	n/a	n/a	US$2b
Sep 30 2023	n/a	n/a	US$2b
Jun 30 2023	US$4m	US$1m	US$2b
Mar 31 2023	n/a	n/a	US$2b
Dec 31 2022	n/a	n/a	US$2b
Sep 30 2022	n/a	n/a	US$2b
Jun 30 2022	US$5m	US$965k	US$2b
Mar 31 2022	n/a	n/a	US$2b
Dec 31 2021	n/a	n/a	US$2b
Sep 30 2021	n/a	n/a	US$2b
Jun 30 2021	US$6m	US$989k	US$2b
Mar 31 2021	n/a	n/a	US$3b
Dec 31 2020	n/a	n/a	US$3b
Sep 30 2020	n/a	n/a	US$2b
Jun 30 2020	US$7m	US$1m	US$2b

Compensatie versus markt: De totale vergoeding ($USD 8.18M ) Paul } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Swiss markt ($USD 4.76M ).

Compensatie versus inkomsten: De vergoeding van Paul is het afgelopen jaar met meer dan 20% gestegen.

CEO

Paul McKenzie (58 yo)

1.6yrs

Tenure

US$8,183,842

Compensatie

Dr. Paul F. McKenzie, Ph.D. (Chemical Engineering), has been Chief Operating Officer at CSL Behring LLC since 2019. Dr. McKenzie serves as Chief Operating Officer at CSL Plasma Inc. Dr. McKenzie had been C...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Paul McKenzie	MD, CEO & Executive Director	1.6yrs	US$8.18m	0.0056% CHF 4.7m
Joy Linton	Interim Executive Vice President of CSL Behring	less than a year	US$3.73m	0.0025% CHF 2.1m
Andy Schmeltz	Executive Vice President of CSL Behring Business Unit (Leave of Absence)	1.3yrs	US$4.07m	0.00044% CHF 369.7k
John A. Levy	Interim Chief Financial Officer	less than a year	geen gegevens	geen gegevens
Chris Cooper	Head of Investor Relations	no data	geen gegevens	geen gegevens
Gregory Boss	Executive VP of Legal & General Counsel	15.8yrs	US$2.31m	geen gegevens
Roanne Parry	Chief Human Resources Officer	less than a year	geen gegevens	geen gegevens
Karen Etchberger	Executive Vice President of Quality & Business Services	14.5yrs	US$2.14m	geen gegevens
Jemimah Brennan	Head of Communications - Asia Pacific	no data	geen gegevens	geen gegevens
Andrew Nash	Senior Vice President of Research	no data	geen gegevens	geen gegevens
William Mezzanotte	Executive VP & Head of Research and Development	6yrs	US$2.14m	geen gegevens
Mark Hill	Chief Digital Information Officer & Executive VP	4yrs	geen gegevens	geen gegevens

1.6yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van CSJ wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.6 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Paul McKenzie	MD, CEO & Executive Director	1.8yrs	US$8.18m	0.0056% CHF 4.7m
Megan Clark	Independent Non Executive Director	8.7yrs	US$242.44k	0.0011% CHF 915.8k
Alison Watkins	Independent Non-Executive Director	3.2yrs	US$240.56k	0.00077% CHF 647.0k
Carolyn Hewson	Independent Non-Executive Director	4.8yrs	US$237.09k	0.00047% CHF 394.9k
Brian McNamee	Independent Non-Executive Chairman	6.7yrs	US$604.85k	0.026% CHF 22.0m
Robert Cuthbertson	Non-Independent Non-Executive Director	6yrs	US$221.35k	0.015% CHF 12.3m
Duncan Maskell	Independent Non-Executive Director	3.2yrs	US$190.94k	0.00035% CHF 294.1k
Marie McDonald	Independent Non-Executive Director	11.2yrs	US$215.19k	0.00088% CHF 739.4k
Samantha Lewis	Independent Non-executive Director	less than a year	US$91.12k	0.00041% CHF 344.5k
Elaine Sorg	Independent Non-Executive Director	less than a year	geen gegevens	geen gegevens

4.0yrs

Gemiddelde duur

63.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van CSJ wordt beschouwd als ervaren (gemiddelde ambtstermijn 4 jaar).

CSL Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

CSL Appoints Jeffrey Ball as First Chief Sustainability Officer

CSL Limited, Annual General Meeting, Oct 09, 2024

CSL Limited, Annual General Meeting, Oct 11, 2023

CSL Limited Announces Management Changes

CSL Limited Announces Chief Executive Officer Changes

High number of new directors

Recent updates

CSL Vifor and Travere Therapeutics Announces Swissmedic Approval of FILSPARI (Sparsentan) for the Treatment of IgA Nephropathy

Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics Holdings Inc.'s Updated Self-Amplifying mRNA Covid-19 Vaccine for Protection Against JN.1 Strain

CSL Limited to Report First Half, 2025 Results on Feb 11, 2025

Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine

CSL Vifor and Travere Therapeutics Announces European Commission Approves FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy

CSL Seqirus Confirms Full Preparation to Implement the Fda's Vaccines and Related Biological Products Advisory Committee

Upcoming dividend of US$1.19 per share

First half dividend of US$1.19 announced

First half 2024 earnings released: EPS: US$3.94 (vs US$3.37 in 1H 2023)

CSL Limited Announces Estimate Distribution for the Six Months Ended December 31, 2023, Payable on April 3, 2024

CSL Announces Top-Line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I (Human)

New minor risk - Financial position

CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicronba BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster Booster

CSL Limited to Report Fiscal Year 2024 Results on Jul 30, 2024

CSL Behring's HEMGENIX (Etranacogene Dezaparvovec-Drlb) Demonstrates At Three Years Post-T Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia B

Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the First Self-Amplifying mRNA Vaccine Approves for COVID in Adults

Health Canada Authorizes Csl's Hemgenix(R) (Etranacogene Dezaparvovec) as First Gene Therapy for Hemophilia B

CSL Limited Reaffirms Financial Outlook for Fiscal Year 2024

CSL Seqirus Announces Data from Three Studies Supporting the Clinical, Public Health Benefit and Cost Savings Associated with Cell-Based and Adjuvanted Influenza Vaccines

CSL Seqirus Shares Data Demonstrating the Potential for Influenza Vaccination to Reduce the Burden on Healthcare Resources

Arcturus Therapeutics Holdings Inc. and Csl Seqirus Announce European Medicines Agency Validates Marketing Authorization Application for Arct-154 Vaccine to Prevent Covid-19

CSL Appoints Jeffrey Ball as First Chief Sustainability Officer

CSL Limited, Annual General Meeting, Oct 09, 2024

CSL Limited to Report Fiscal Year 2023 Results on Aug 15, 2023

CSL Limited Announces Interim Dividend, Payable on 5 April 2023

CSL Limited, Annual General Meeting, Oct 11, 2023

CSL Limited to Report First Half, 2023 Results on Feb 14, 2023

SAB Biotherapeutics Novel DiversitAb™ Platform Proven to Develop Anti-idiotype Antibodies to Help Treat Autoimmune Diseases

CSL Limited Announces Management Changes

CSL Limited Announces Chief Executive Officer Changes

CSL Limited Announces FDA Approval of First Gene Therapy for Adults with Hemophilia B

CSL Limited Announces Positive Preclinical Data for Self-Amplifying Messenger RNA (sa-mRNA) Influenza Vaccine Candidates

CSL Limited Announces Positive Top-Line Phase 3 Results for Garadacimab as Preventive Treatment in Patients with Hereditary Angioedema (HAE)

CSL Limited Announces Final Dividend for the Period Ended June 30, 2022, Payable on 6 September 2022

First half 2022 earnings: EPS in line with analyst expectations despite revenue beat

CSL Limited Provides Earnings Guidance for the Fiscal Year 2022

CSL Limited has completed a Follow-on Equity Offering in the amount of AUD 750.028364 million.

CSL Limited (ASX:CSL) entered into a definitive agreement to launch public tender offer to acquire Vifor Pharma AG (SWX:VIFN) from Patinex AG and other for CHF 10.9 billion.

Vifor Pharma and CSL Confirm Merger Talks

Centerview Reportedly Role in Vifor Sale

Vifor Says Regularly in Talks with Other Market Participants After Reports

Seqirus Announces U.S. FDA Approval for Multi-Dose Vial Presentation of First-Ever Adjuvanted, Cell-Based Pandemic Influenza Vaccine

High number of new directors

CSL Limited Provides Financial Guidance for Fiscal 2022

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd